1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((2-methoxyphenyl)amino) pyrimidin-4-yl)oxy)naphthalen-1-yl)urea | 1429399-09-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((2-methoxyphenyl)amino) pyrimidin-4-yl)oxy)naphthalen-1-yl)urea
• 英文别名: US9724347, Example 5；1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(2-methoxyanilino)pyrimidin-4-yl]oxynaphthalen-1-yl]urea
• CAS: 1429399-09-6
• 化学式: C₃₆H₃₅N₇O₃
• 分子量: 613.719
• InChiKey: OKZIGNXMBPUUKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  46
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
  申请人：Respivert Limited

  公开号：EP2578582A1

  公开（公告）日：2013-04-10

  There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

  提供了化合物的公式（I），这些化合物是p38丝裂原活化蛋白激酶酶家族的抑制剂，可用于治疗，包括药物组合的使用，特别是用于治疗炎症性疾病，包括肺部炎症性疾病，如哮喘和慢性阻塞性肺疾病（COPD）。
• [EN] L-PYRAZOLYL-3- (4- ( (2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- 1 - YL) UREAS AS P3I MAP KINASE INHIBITORS<br/>[FR] L-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4-YL)OXY)NAPHTALÈN-1-YL)URÉES EN TANT QU'INHIBITEURS DE P3I MAP KINASE
  申请人：RESPIVERT LTD

  公开号：WO2013050756A1

  公开（公告）日：2013-04-11

  There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

  提供了一种化合物的化学式（I），它们是p38丝裂原活化蛋白激酶酶家族的抑制剂，可用于治疗，包括在药物组合中的使用，特别是用于治疗炎症性疾病，包括肺部炎症性疾病，如哮喘和慢性阻塞性肺病（COPD）。
• 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors
  申请人：Respivert Limited

  公开号：US10238658B2

  公开（公告）日：2019-03-26

  There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

  本发明提供的式(I)化合物是 p38 丝裂原活化蛋白激酶家族的抑制剂，可用于治疗，包括药物组合，特别是治疗炎症性疾病，包括肺部炎症性疾病，如哮喘和慢性阻塞性肺病。
• 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
  申请人：Respivert Limited

  公开号：US10813932B2

  公开（公告）日：2020-10-27

  There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

  本发明提供的式(I)化合物是 p38 丝裂原活化蛋白激酶家族的抑制剂，可用于治疗，包括药物组合，特别是治疗炎症性疾病，包括肺部炎症性疾病，如哮喘和慢性阻塞性肺病。
• L-PYRAZOLYL-3- (4- ( (2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- 1 - YL) UREAS AS P3I MAP KINASE INHIBITORS
  申请人：Respivert Limited

  公开号：EP2763983A1

  公开（公告）日：2014-08-13